

## APPENDIX 7: DETAILED PATIENT CHARACTERISTICS

**TABLE 83: TREATMENT-NAIVE**

INCLUDED STUDIES	ITT, N <sup>a</sup>	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	HEPATITIS C GENOTYPE AND SUBTYPE (%)									PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
					1	G1a	1b	2	3	4	5	6	COMBINED OR OTHER	CIRR-HOTIC <sup>b</sup>	NON-CIRRHOTIC	
Afdhal et al., 2014 ION-1	214	SOF12 + LDV12	52 (mean) (18 to 75)	59	--	67	31	-	-	-	-	-	-	16	84	6.4 (0.69)
	217	SOF24 + LDV24	53 (mean) (22 to 80)	64	--	67	31	-	-	-	-	-	-	15	85	6.3 (0.68)
	217	SOF12 + LDV12 + RBV12	52 (mean) (18 to 78)	59	--	68	31	-	-	-	-	-	-	15	85	6.4 (0.64)
	217	SOF24 + LDV24 + RBV24	53 (mean) (24 to 77)	55	--	66	33	-	-	-	-	-	-	17	83	6.3 (0.65)
Feld et al., 2014 SAPPHIRE-I	477	PAR/RIT12 + OMB12 + DAS12 + RBV12	49.4 (18 to 70.0)	57	100	68	32	-	-	-	-	-	-	-	100	6.40 (0.62)
Ferenci et al., 2014 PEARL-III	209	PAR/RIT12 + OMB12 + DAS12	49.2 (12.0)	41	100	0	100	-	-	-	-	-	-	0	100	6.33 (0.67)
Ferenci et al., 2014 PEARL-IV	100	PAR/RIT12 + OMB12 + DAS12 + RBV12	51.6 (11.0)	70	100	100	-	-	-	-	-	-	-	0	100	6.64 (0.50)
Jacobson et al., 2014 QUEST-1	130	PR48	48 (36 to 54)	57	100	57	43	-	-	-	-	-	-	13	87	-
	264	SIM12 PR24-48 RGT	48 (39 to 54)	56	100	56	44	-	-	-	-	-	-	12	87	-
Kohli et al., 2015	20	SOF12 + LDV12	57 (8)	70	100	55	45	-	-	-	-	-	-	-	-	-

INCLUDED STUDIES	ITT, N <sup>a</sup>	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	HEPATITIS C GENOTYPE AND SUBTYPE (%)									PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
					1	G1a	1b	2	3	4	5	6	COMBINED OR OTHER	CIRR-HOTIC <sup>b</sup>	NON-CIRRHOTIC	
Kowdley et al., 2013 ATOMIC	52	SOF12 + PR12	51 (9.8)	67	100	77	23	-	-	-	-	-	0	-	100	6.5 (0.7)
Kowdley et al., 2014 ION-3	216	SOF12 + LDV12	53 (20 to 71)	59	100	80	20	-	-	-	-	-	-	-	100	6.4 (0.8)
	215	SOF8 + LDV8	53 (22 to 75)	60	100	80	20	-	-	-	-	-	< 1	-	100	6.5 (0.8)
	216	SOF8 + LDV8 + RBV8	51 (21 to 71)	54	100	80	20	-	-	-	-	-	-	-	100	6.4 (0.7)
Lawitz et al., 2013 FISSION	256	SOF12 + RBV12	48 (20 to 72)	67	< 2	1	< 1	27	71	-	-	-	< 2	20	80	6.4 (0.7)
	243	PR24	48 (19 to 77)	64	-	-	-	28	72	-	-	-	-	21	79	6.0 (0.8)
Lawitz et al., 2013 NEUTRINO	327	SOF12 + PR12	52 (19 to 70)	64	89	69	20	-	-	9	< 1	2	< 1	17	83	6.4 (0.7)
Lawitz et al., 2013-1	47	SOF12 + PR24-48 RGT	51.4 (9.4)	45	100	74	26	-	-	-	-	-	-	-	100	6.4 (0.8) IU/mL
	26	PR48	48.6 (9.4)	73	100	77	23	-	-	-	-	-	-	-	100	6.5 (0.8)
Manns et al., 2014 QUEST-2	134	PR48	47 (18 to 73)	57	100	41	58	-	-	-	-	-	2	11	89	-
	257	SIM12 PR24-48 RGT	46 (18 to 73)	54	100	41	58	-	-	-	-	-	< 1	7	93	-
Osinusi et al., 2013 SPARE-1	10	SOF24 + RBV24	54 (50 to 57)	40	100	60	40	-	-	-	-	-	-	-	-	6.8 (6 to 7.1)

INCLUDED STUDIES	ITT, N <sup>a</sup>	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	HEPATITIS C GENOTYPE AND SUBTYPE (%)									PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
					1	G1a	1b	2	3	4	5	6	COMBINED OR OTHER	CIRR-HOTIC <sup>b</sup>	NON-CIRRHOTIC	
Osinusi et al., 2013 SPARE-2	25	SOF24 + RBV24	54 (51 to 56)	76	100	80	20	-	-	-	-	-	-	-	-	6.2 (5.4 to 6.4)
	25	SOF24 + RBV (low dose) 24	55 (48 to 59)	56	100	64	36	-	-	-	-	-	-	-	-	6.1 (5.5 to 6.3)
Osinusi et al., 2015	50	SOF12 + LDV12	58-59 (median) (51 to 63)	74	100	78	20	0	0	0	0	0	2	-	100	5.948 (--)
Sulkowski et al., 2013-1	6	PR48	48 (42 to 65)	67	100	50	33	-	-	-	-	-	17	0	100	6.2 (0.5)
	7	T12 PR48 q8	39 (34 to 50)	86	100	43	57	-	-	-	-	-		0	100	6.7 (0.5)
Sulkowski et al., 2013-2	8	PR48	39 (26 to 53)	88	100	63	38	-	-	-	-	-		0	100	6.5 (0.6)
	15	T12 PR48 q8	52 (36 to 59)	87	100	80	20	-	-	-	-	-		0	100	6.4 (0.9)
Sulkowski et al., 2013 P05411	34	PR48	45.1 (9.8)	65	100	74	26	-	-	-	-	-		3	97	6.8 (6.2 to 7.1)
	64	B44 PR48	42.9 (8.3)	72	98	80	19	-	-	-	-	2		3	97	6.6 (6.2 to 7.0)
Hassanein et al., 2015	11	DCV12 + ASU12 + BEC12 (75 mg b.i.d.)	56 (37 to 66)	64	0	0	0	0	0	100	0	0	-	0	100	5.6 (0.66)
	10	DCV12 + ASU12 + BEC12	50 (22 to 57)	60	0	0	0	0	0	100	0	0	-	0	100	5.7 (0.70)

INCLUDED STUDIES	ITT, N <sup>a</sup>	TREATMENT GROUPS	AGE (YEARS) MEAN (SD)/ MEDIAN (RANGE)	% MALE	HEPATITIS C GENOTYPE AND SUBTYPE (%)									PRESENCE OR ABSENCE OF CIRRHOSIS (%)		BASELINE VIRAL LOAD, MEAN LOG <sub>10</sub> (SD)
					1	G1a	1b	2	3	4	5	6	COMBINED OR OTHER	CIRR-HOTIC <sup>b</sup>	NON-CIRRHOTIC	
		(150 mg b.i.d.)														
Lawitz et al., 2013-2	25	SOF12 + PR12	47.2 (11.1)	64	-	-	-	60	40	-	-	-	-	-	100	6.1 (0.8) IU/mL
Rodriguez-Torres et al., 2015	23	SOF12 + PR12	47 (29 to 59)	78	83	65	17	4	9	4	0	0	0	-	100	6.586 (0.872)
Zeuzem et al., 2015 C-EDGE	316	GRZ12 + ELB12	52.2 (11.1)/54 (20 to 78)	54	92	50	42	-	-	6	-	3		22	78	6.4 (6.5)

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; G = genotype; GRZ = grazoprevir; ITT = intention-to-treat; IU = international unit; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SD = standard deviation; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

<sup>a</sup> Some numbers refer to the numbers of patients who were randomized and treated. For single-arm studies, the number refers to those who were enrolled and treated.

<sup>b</sup> The numbers here all refer to compensated cirrhosis, because patients with hepatic decompensation were excluded in treatment-naïve studies.